Recent studies conducted at Yale, discover an alternative therapy against HIV that reduces viral replication and increases immune cells in individuals whose advanced infection is resistant to current medications.


Specifically, the combination with other anti-HIV drugs, therapy may be a “promising strategy for patients who have run out of effective treatment options,” the researchers said.

Existing pharmacological therapies can not suppress the virus for certain people, leading to drug resistance and worsening disease. In March 2018, the American Medicines Agency approved this new drug called Ibalizumab, a drug aimed at the primary recipient for the entry of HIV into CD4 T cells, thus preventing HIV from entering the target cells. The research team found that after a week with ibalizumab, 83% of the patients in the study experienced a significant decrease in their viral load, reaching an undetectable viral load after 25 weeks.

“These patients had extremely advanced HIV and resistant viruses with limited options. Seeing viral suppression in a significant percentage of these patients at six months is encouraging. represents a new mechanism of action much needed for patients who have highly resistant HIV, “says one of its main advocates, Brinda Emu.

Clinical Diagnostic Laboratory Technician and Center Manager, specialist in the field of Sexually Transmitted Diseases for more than 6 years. Awarded in 2018 the Award for Labor Excellence in the field of medicine for his work in charge of the clinic.

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies
WhatsApp chat